These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 23455440)

  • 1. Epigenetic regulation of cholinergic receptor M1 (CHRM1) by histone H3K9me3 impairs Ca(2+) signaling in Huntington's disease.
    Lee J; Hwang YJ; Shin JY; Lee WC; Wie J; Kim KY; Lee MY; Hwang D; Ratan RR; Pae AN; Kowall NW; So I; Kim JI; Ryu H
    Acta Neuropathol; 2013 May; 125(5):727-39. PubMed ID: 23455440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remodeling of heterochromatin structure slows neuropathological progression and prolongs survival in an animal model of Huntington's disease.
    Lee J; Hwang YJ; Kim Y; Lee MY; Hyeon SJ; Lee S; Kim DH; Jang SJ; Im H; Min SJ; Choo H; Pae AN; Kim DJ; Cho KS; Kowall NW; Ryu H
    Acta Neuropathol; 2017 Nov; 134(5):729-748. PubMed ID: 28593442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetics of Huntington's Disease.
    Bassi S; Tripathi T; Monziani A; Di Leva F; Biagioli M
    Adv Exp Med Biol; 2017; 978():277-299. PubMed ID: 28523552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ATRX induction by mutant huntingtin via Cdx2 modulates heterochromatin condensation and pathology in Huntington's disease.
    Lee J; Hong YK; Jeon GS; Hwang YJ; Kim KY; Seong KH; Jung MK; Picketts DJ; Kowall NW; Cho KS; Ryu H
    Cell Death Differ; 2012 Jul; 19(7):1109-16. PubMed ID: 22240898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PRMT5- mediated symmetric arginine dimethylation is attenuated by mutant huntingtin and is impaired in Huntington's disease (HD).
    Ratovitski T; Arbez N; Stewart JC; Chighladze E; Ross CA
    Cell Cycle; 2015; 14(11):1716-29. PubMed ID: 25927346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
    Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
    Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of H3K4me3 in Transcriptional Regulation Is Altered in Huntington's Disease.
    Dong X; Tsuji J; Labadorf A; Roussos P; Chen JF; Myers RH; Akbarian S; Weng Z
    PLoS One; 2015; 10(12):e0144398. PubMed ID: 26636336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of inositol 1,4,5-trisphosphate receptors in pathogenesis of Huntington's disease and spinocerebellar ataxias.
    Bezprozvanny I
    Neurochem Res; 2011 Jul; 36(7):1186-97. PubMed ID: 21210219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism.
    Seong IS; Ivanova E; Lee JM; Choo YS; Fossale E; Anderson M; Gusella JF; Laramie JM; Myers RH; Lesort M; MacDonald ME
    Hum Mol Genet; 2005 Oct; 14(19):2871-80. PubMed ID: 16115812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic mechanisms of neurodegeneration in Huntington's disease.
    Lee J; Hwang YJ; Kim KY; Kowall NW; Ryu H
    Neurotherapeutics; 2013 Oct; 10(4):664-76. PubMed ID: 24006238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of disease: Histone modifications in Huntington's disease.
    Sadri-Vakili G; Cha JH
    Nat Clin Pract Neurol; 2006 Jun; 2(6):330-8. PubMed ID: 16932577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic background modifies nuclear mutant huntingtin accumulation and HD CAG repeat instability in Huntington's disease knock-in mice.
    Lloret A; Dragileva E; Teed A; Espinola J; Fossale E; Gillis T; Lopez E; Myers RH; MacDonald ME; Wheeler VC
    Hum Mol Genet; 2006 Jun; 15(12):2015-24. PubMed ID: 16687439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.
    Hansson O; Castilho RF; Korhonen L; Lindholm D; Bates GP; Brundin P
    J Neurochem; 2001 Aug; 78(4):694-703. PubMed ID: 11520890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant huntingtin activates Nrf2-responsive genes and impairs dopamine synthesis in a PC12 model of Huntington's disease.
    van Roon-Mom WM; Pepers BA; 't Hoen PA; Verwijmeren CA; den Dunnen JT; Dorsman JC; van Ommen GB
    BMC Mol Biol; 2008 Oct; 9():84. PubMed ID: 18844975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic Mechanisms Involved in Huntington's Disease Pathogenesis.
    Glajch KE; Sadri-Vakili G
    J Huntingtons Dis; 2015; 4(1):1-15. PubMed ID: 25813218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
    Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection by dietary restriction in the YAC128 mouse model of Huntington's disease: Relation to genes regulating histone acetylation and HTT.
    Moreno CL; Ehrlich ME; Mobbs CV
    Neurobiol Dis; 2016 Jan; 85():25-34. PubMed ID: 26485309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pathogenic mechanism in Huntington's disease involves small CAG-repeated RNAs with neurotoxic activity.
    Bañez-Coronel M; Porta S; Kagerbauer B; Mateu-Huertas E; Pantano L; Ferrer I; Guzmán M; Estivill X; Martí E
    PLoS Genet; 2012; 8(2):e1002481. PubMed ID: 22383888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitogen- and stress-activated protein kinase 1-induced neuroprotection in Huntington's disease: role on chromatin remodeling at the PGC-1-alpha promoter.
    Martin E; Betuing S; Pagès C; Cambon K; Auregan G; Deglon N; Roze E; Caboche J
    Hum Mol Genet; 2011 Jun; 20(12):2422-34. PubMed ID: 21493629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased calbindin-D28k immunoreactivity in striatal projection neurons of R6/2 Huntington's disease transgenic mice.
    Sun Z; Wang HB; Deng YP; Lei WL; Xie JP; Meade CA; Del Mar N; Goldowitz D; Reiner A
    Neurobiol Dis; 2005 Dec; 20(3):907-17. PubMed ID: 15990326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.